Mountain Valley MD (TSE:MVMD)
:MVMD
Want to see TSE:MVMD full AI Analyst Report?
Top Page
Mountain Valley MD
(MVMD)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$0.07
▲(250.00% Upside)
Action:ReiteratedDate:04/19/26
The score is held down primarily by weak financial performance (minimal/declining revenue, sustained losses, and persistent cash burn alongside a sharply reduced equity base). Technicals provide meaningful support due to a clear uptrend and positive momentum, while valuation remains pressured by negative earnings and the absence of a dividend yield.
Positive Factors
Low leverage / minimal debt
Effectively zero reported debt materially lowers financial distress risk and preserves strategic optionality. Over a multi‑month horizon this reduces bankruptcy and interest burden risk, allowing management to allocate scarce cash to R&D or partnerships rather than debt service.
Negative Factors
Persistent negative operating cash flow
Consistent multi‑year cash burn undermines self‑funding ability and forces reliance on external capital. Over months this raises dilution and execution risk, constrains investment in development/commercialization, and shortens runway absent financing or material revenue improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
Effectively zero reported debt materially lowers financial distress risk and preserves strategic optionality. Over a multi‑month horizon this reduces bankruptcy and interest burden risk, allowing management to allocate scarce cash to R&D or partnerships rather than debt service.
Read all positive factors
Mountain Valley MD (MVMD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$24.66M
Dividend YieldN/A
Average Volume (3M)205.59K
Price to Earnings (P/E)―
Beta (1Y)-0.81
Revenue Growth83.87%
EPS Growth-72.88%
CountryCA
Employees1
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,354,950
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.44
Price to Sales (P/S)177.77
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mountain Valley MD Business Overview & Revenue Model
Company Description
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical...
How the Company Makes Money
null...
Mountain Valley MD Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.00K | 49.00K | 60.00K | 0.00 | 110.00K | 0.00 |
| Gross Profit | 18.00K | 49.00K | -346.00K | -446.00K | 70.00K | -430.19K |
| EBITDA | -1.22M | -3.16M | -2.78M | -6.89M | -9.29M | -4.77M |
| Net Income | -5.96M | -7.47M | -7.67M | -7.44M | -9.71M | -8.14M |
Balance Sheet | ||||||
| Total Assets | 594.00K | 2.74M | 8.97M | 16.77M | 25.27M | 31.61M |
| Cash, Cash Equivalents and Short-Term Investments | 316.00K | 1.72M | 5.92M | 9.71M | 14.22M | 19.51M |
| Total Debt | 89.00K | 0.00 | 0.00 | 6.00K | 44.00K | 84.00K |
| Total Liabilities | 130.00K | 209.00K | 258.00K | 591.00K | 422.00K | 1.11M |
| Stockholders Equity | 464.00K | 2.53M | 8.71M | 16.18M | 24.85M | 30.50M |
Cash Flow | ||||||
| Free Cash Flow | -1.07M | -3.91M | -3.80M | -4.85M | -5.68M | -4.31M |
| Operating Cash Flow | -1.07M | -3.90M | -3.30M | -4.79M | -5.59M | -3.86M |
| Investing Cash Flow | 187.00K | -290.00K | -503.00K | 1.89M | -98.00K | -149.00K |
| Financing Cash Flow | 89.00K | 0.00 | -6.00K | -1.60M | 395.00K | 21.78M |
Mountain Valley MD Technical Analysis
Positive
0.02
Price Trends
0.04
Positive
0.03
Positive
0.02
Positive
Market Momentum
<0.01
Positive
60.31
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.04, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 60.31 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.
Mountain Valley MD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$24.66M | -1.56 | -461.32% | ― | 83.87% | -72.88% | |
50 Neutral | C$14.65M | -4.56 | 899.59% | ― | ― | -95.38% | |
48 Neutral | C$35.03M | -2.55 | ― | ― | ― | 32.91% | |
45 Neutral | C$6.92M | 5.19 | ― | ― | -25.05% | 67.74% | |
41 Neutral | C$2.07M | -10.76 | -11.42% | ― | -12.84% | -681.25% | |
40 Underperform | C$1.95M | -1.54 | -271.33% | ― | 15.95% | -1.81% |
* Healthcare Sector Average
TSE:MVMD
Mountain Valley MD
0.07
0.04
116.67%
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-60.00%
TSE:RVV
Revive Therapeutics
0.04
<0.01
16.67%
TSE:PCLO
PharmaCielo
0.05
-0.02
-28.57%
TSE:CANB
CanadaBis Capital
0.02
-0.05
-75.00%
TSE:LOBE
Lobe Sciences
0.11
0.08
214.29%
Mountain Valley MD Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Mountain Valley MD to Raise $2 Million and Wipe Out Debt via Equity Deals
Positive
Mar 31, 2026
Mountain Valley MD Holdings plans a non-brokered private placement of up to 80,000,000 units at $0.025 each to raise as much as $2 million from biotech investors, with each unit comprising one common share and a warrant exercisable at $0.08 for 12...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.